KROS•benzinga•
B of A Securities Downgrades Keros Therapeutics to Neutral, Lowers Price Target to $18
Summary
No summary available.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on June 10, 2025 by benzinga